Clinical response to futibatinib in intrahepatic cholangiocarcinoma with acquired resistance to fibroblast growth factor receptor 2 inhibitors

被引：0
|
作者：
Casalino, S. [1 ]
Gerdes, C. [2 ]
Saborowski, A. [2 ]
Quinzii, A. [1 ]
Zecchetto, C. [1 ]
Sordo, A. [3 ]
Messineo, L. [1 ]
Leta, L. C. [1 ]
Lucin, E. [1 ]
Mendo, L. [1 ]
Pietrobono, S. [1 ]
Vogel, A. [4 ]
Melisi, D. [1 ]
机构：
[1] Univ Verona, Digest Mol Clin Oncol Res Unit, Verona, Italy
[2] MHH, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany
[3] Univ Padua, Unit Biostat Epidemiol & Publ Hlth, Dept Cardiac Thorac Vasc Sci & Publ Hlth, Padua, Italy
[4] Princess Margaret Canc Ctr, Div Gastroenterol & Hepatol, Toronto, ON, Canada
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.447
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
304P
引用
收藏
页码：S128 / S129
页数：2
相关论文
共 50 条
  • [41] Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer
    Garje, Rohan
    An, Josiah
    Obeidat, Mohammad
    Kumar, Kranthi
    Yasin, Hesham A.
    Zakharia, Yousef
    ONCOLOGIST, 2020, 25 (11): : E1711 - E1719
  • [42] Ocular toxicities of fibroblast growth factor receptor inhibitors: A review
    Hsu, Jerry
    Francis, Jasmine H.
    Ahmad, Sumayya
    SURVEY OF OPHTHALMOLOGY, 2024, 69 (01) : 34 - 41
  • [43] The natural history of fibroblast growth factor receptor (FGFR)-altered cholangiocarcinoma (CCA).
    Goyal, Lipika
    Lamarca, Angela
    Strickler, John H.
    Cecchini, Michael
    Ahn, Daniel H.
    Baiev, Islam
    Boileve, Alice
    Tazdait, Melodie
    Hannan, Lindsay Marie
    Jia, Jingquan
    Marble, Hetal Desai
    Barzi, Afsaneh
    Sahai, Vaibhav
    Lennerz, Jochen K.
    Kelley, Robin Kate
    Bekaii-Saab, Tanios S.
    Javle, Milind M.
    Uboha, Nataliya Volodymyrivna
    Harris, William P.
    Hollebecque, Antoine
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [44] Histologic Evolution of Lung Adenocarcinomas with Acquired Resistance to Epidermal Growth Factor Receptor (EGFR) Inhibitors
    Cai, G.
    Gettinger, S. N.
    Walther, Z.
    Wurtz, A. K.
    Pirazzoli, V.
    Bao, Y.
    Homer, R. J.
    Politi, K.
    MODERN PATHOLOGY, 2014, 27 : 474A - 474A
  • [45] Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors
    Chen, Justin A.
    Riess, Jonathan W.
    JOURNAL OF THORACIC DISEASE, 2020, 12 (05) : 2859 - 2876
  • [46] Histologic Evolution of Lung Adenocarcinomas with Acquired Resistance to Epidermal Growth Factor Receptor (EGFR) Inhibitors
    Cai, G.
    Gettinger, S. N.
    Walther, Z.
    Wurtz, A. K.
    Pirazzoli, V.
    Bao, Y.
    Homer, R. J.
    Politi, K.
    LABORATORY INVESTIGATION, 2014, 94 : 474A - 474A
  • [47] Efficacy of futibatinib, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in breast cancer models with FGFR alterations
    Saridogan, Turcin
    Akcakanat, Argun
    Zhao, Ming
    Evans, Kurt W.
    Yuca, Erkan
    Scott, Stephen
    Kirby, Bryce P.
    Zheng, Xiaofeng
    Damodaran, Senthil
    Meric-Bernstam, Funda
    CANCER RESEARCH, 2022, 82 (04)
  • [48] Clinical spectrum of fibroblast growth factor receptor mutations
    Passos-Bueno, MR
    Wilcox, WR
    Jabs, EW
    Sertié, AL
    Alonso, LG
    Kitoh, H
    HUMAN MUTATION, 1999, 14 (02) : 115 - 125
  • [49] Fibroblast Growth Factor Receptor 2 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Cholangiocarcinoma
    Arai, Yasuhito
    Totoki, Yasushi
    Hosoda, Fumie
    Shirota, Tomoki
    Hama, Natsuko
    Nakamura, Hiromi
    Ojima, Hidenori
    Furuta, Koh
    Shimada, Kazuaki
    Okusaka, Takuji
    Kosuge, Tomoo
    Shibata, Tatsuhiro
    HEPATOLOGY, 2014, 59 (04) : 1427 - 1434
  • [50] Potent, Selective Inhibitors of Fibroblast Growth Factor Receptor Define Fibroblast Growth Factor Dependence in Preclinical Cancer Models
    Squires, Matthew
    Ward, George
    Saxty, Gordan
    Berdini, Valerio
    Cleasby, Anne
    King, Peter
    Angibaud, Patrick
    Perera, Tim
    Fazal, Lynsey
    Ross, Douglas
    Jones, Charlotte Griffiths
    Madin, Andrew
    Benning, Rajdeep K.
    Vickerstaffe, Emma
    O'Brien, Alistair
    Frederickson, Martyn
    Reader, Michael
    Hamlett, Christopher
    Batey, Michael A.
    Rich, Sharna
    Carr, Maria
    Miller, Darcey
    Feltell, Ruth
    Thiru, Abarna
    Bethell, Susanne
    Devine, Lindsay A.
    Graham, Brent L.
    Pike, Andrew
    Cosme, Jose
    Lewis, Edward J.
    Freyne, Eddy
    Lyons, John
    Irving, Julie
    Murray, Christopher
    Newell, David R.
    Thompson, Neil T.
    MOLECULAR CANCER THERAPEUTICS, 2011, 10 (09) : 1542 - 1552
12345